Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Johnson and Johnson
AstraZeneca
Merck
Harvard Business School

Last Updated: October 6, 2022

TAMOXIFEN CITRATE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Tamoxifen Citrate, and when can generic versions of Tamoxifen Citrate launch?

Tamoxifen Citrate is a drug marketed by Actavis Labs Fl Inc, Aegis Pharms, Apotex, Eugia Pharma, Ivax Sub Teva Pharms, Mayne Pharma, Mylan, Pharmachemie, Roxane, Teva, and Zydus Pharms. and is included in twelve NDAs.

The generic ingredient in TAMOXIFEN CITRATE is tamoxifen citrate. There are sixteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the tamoxifen citrate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Tamoxifen Citrate

A generic version of TAMOXIFEN CITRATE was approved as tamoxifen citrate by ACTAVIS LABS FL INC on February 20th, 2003.

  Sign up for a Free Trial

Drug patent expirations by year for TAMOXIFEN CITRATE
Drug Prices for TAMOXIFEN CITRATE

See drug prices for TAMOXIFEN CITRATE

Drug Sales Revenue Trends for TAMOXIFEN CITRATE

See drug sales revenues for TAMOXIFEN CITRATE

Recent Clinical Trials for TAMOXIFEN CITRATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Sharif Medical Research CenterPhase 2
Baylor College of MedicineEarly Phase 1
The Joshua Frase Foundation USAPhase 1/Phase 2

See all TAMOXIFEN CITRATE clinical trials

Pharmacology for TAMOXIFEN CITRATE

US Patents and Regulatory Information for TAMOXIFEN CITRATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actavis Labs Fl Inc TAMOXIFEN CITRATE tamoxifen citrate TABLET;ORAL 070929-001 Feb 20, 2003 AB RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Roxane TAMOXIFEN CITRATE tamoxifen citrate TABLET;ORAL 076027-001 Feb 20, 2003 DISCN No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Apotex TAMOXIFEN CITRATE tamoxifen citrate TABLET;ORAL 090878-001 Sep 23, 2011 AB RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Actavis Labs Fl Inc TAMOXIFEN CITRATE tamoxifen citrate TABLET;ORAL 076179-002 Feb 20, 2003 DISCN No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Harvard Business School
Baxter
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.